CDK9 and prostate carcinoma: Furthermore, deregulations in the CDK9-related pathway were reported in a number of human malignancies, such as lymphomas [66, 128], neuroblastoma [67], primary neuroectodermal tumor [67], rhabdomyosarcoma [68], and prostate cancer [129].